Turn business strategy from an art into a computational science — a shared vocabulary humans and AI can both reason in.
A genome is one value per dimension: CREATE_NEW · BUILD · PRODUCT · AI_AUTONOMOUS · COMPOUND · …
Two tools, one substrate. Nova reads what a business is made of. Genome Sequencing reasons about what it can become.
Burns off the packaging; exposes the substrate.
Genome SequencingThe strategic identity of the business — composed, sequenced, and compared.
Nova is cause, genome is choice. The substrate is what you have after the burn; the genome is what you decide to plant in it. The same risk-substrate can fuel an Accountable Intermediary or a Verification Provider — different choices, same input.
Identity, context, and analysis are distinct levels — and they don't mix. Identity is intrinsic; context is extrinsic; analysis is derived.
What the business is.
Where it operates.
What we conclude.
A genome is a composition across orthogonal dimensions — not a bucket. Pick one value per dimension; reading down is the sequence. Load a shape to see how a real composition lights up, or click values to compose your own.
Closed, small enums (3–6 values each) force categorical decisions instead of analyst drift. Named shapes are emergent — a label for a composition, not a primitive.
Context is extrinsic — it would change if the company moved markets, geography, or segment. The same genome runs differently in different environments.
Where you compete. A boundary plus a concrete instance — primary, with optional secondary markets.
VERTICAL · healthcare, PERSONA · developers, USE_CASE · payments
Home region and the markets you're expanding into — north-america, europe, asia-pacific, and beyond.
The rules you operate under, and the ones that work for you. Plug-ins enforce these against the genome.
Domain experts contribute industry plug-ins: constraints that validate a genome against real-world rules, plus hard-won insights. Registered in a plug-in registry; extended from a contribution template.
EPHEMERAL — compliance & continuity of care.HIPAA is table stakes for US ops.
Provider workflow integration drives adoption.
Outcome pricing aligns with value-based care.
CENTRALIZED topology for latency.Banking partnerships are essential.
Compliance can be 20–30% of early budget.
B2B fintech sells faster than consumer.
EPHEMERAL delivery models.Omnichannel is table stakes.
Return logistics make or break unit economics.
Social commerce growing 30%+ annually.
Each plug-in is an IndustryPlugin — id · constraints · insights · patterns — registered in a PluginRegistry and matched to a market by industry. A contribution template lets any domain expert add one: define the constraint, set ERROR or WARNING, write the message explaining why it exists.
Compose a genome in a context and the toolkit derives the analysis — pattern matches, moats, risks, opportunities, competitive position — plus market-scale moves like white-space detection and pattern evolution.
Nearest known genomes, with a 0–1 similarity score. same genome, same fight.
Each scored by probability × impact, with a mitigation.
Sized LOW → TRANSFORMATIVE, with a timeframe and the requirements to capture them.
Direct competitors, substitute threats, market maturity, differentiation level.
White-space detection across a boundary, successful-pattern lookup, and pattern evolution over time.
Execution metrics track the genome live — stage (PLANNED → SCALING → MATURE → PIVOTING), market fit, growth, and a pivot history of from → to with the reason.
Adding a named genome is free — it's just a label for a composition the dimensions already produce. Adding a dimension is constitutional. These are shorthand for sequences seen often enough to name.
The vocabulary is positioned to stay stable and citable for 5+ years. That requires a constitution — the rules that govern what belongs in the genome and what does not. Every extension must cite which principles it satisfies. Taste is not a justification.
The genome is a composition across dimensions, not a named bucket. Naming a composition is free; adding a dimension is constitutional.
Swapping a value must produce a different business — different sales motion, pricing, competitors — not different features.
Dimensions are independent. Knowing one shouldn't predict another. Cross-products must populate, not cluster on the diagonal.
Identity, context, and analysis don't mix. Intrinsic vs. extrinsic vs. derived — conflating them drifts the vocabulary toward marketing.
What you have after the burn (Nova) is not a genome dimension. Assets are substrate; what you build on them is the genome.
A stranger must apply the dimension to a new ISV correctly, with no author in the room. Insider vocabulary disqualifies.
3–6 mutually exclusive, collectively exhaustive values per dimension. Soft ceiling of six — a seventh signals a hidden split.
Designed for agents to apply at scale; readable by humans as a side effect. Uppercase enums, explicit compositions.
Two ISVs with identical genomes are in the same competition. Resolution is tuned to land dozens of meaningful clusters — not one, not hundreds.
New dimension/value/shape needs: statement, principle citations (P2+P4 mandatory, P3 demonstrated), two real examples, backward-compat note, substrate companion edit.
The DSL is descriptive vocabulary — it makes legible what business you're in, what you're moving to, and what the gap requires. It does not prescribe the right move; that decision is the ISV's. The principles govern the language, not the theory.